openPR Logo
Press release

Platelet Rich Plasma (PRP) Market to expand at a CAGR of 6.6% through 2016 to 2024

10-11-2016 12:06 PM CET | Health & Medicine

Press release from: Future Market Insights

Platelet Rich Plasma (PRP) Market to expand at a CAGR of 6.6%

The market for platelet rich plasma (PRP) Europe is expected to reach US$ 37.5 Mn in 2016, up from US$ 35.3 Mn in 2015. Adoption of platelet rich plasma in treating musculoskeletal injuries, including tennis elbow, Achilles tendinopathy, and plantar fasciitis, will continue to drive revenues. PRP therapy is also gaining traction in treating sports-related and geriatric injuries, owing to its minimally invasive procedure and quicker recovery time.

By product type, PRP kits will continue to outsell instruments, accounting for over 75% revenue share of the market in 2016. Among the various platelet rich plasma kits, autologous kits will account for the highest demand on the basis of blood type, representing a market value worth US$ 24.2 Mn. P-PRF kits—valued at US$ 10 Mn in 2015—will witness the highest growth by end-product type, increasing at 8.6% in 2016.

By application, adoption of PRP therapy will continue to remain highest in the treatment of knee and elbow injuries. While knee application segment revenues will grow by 7.2%, elbow application segment revenues are projected to grow by 6.3%. Use of PRP therapy in the treatment of ever-increasing incidences of osteoarthritis and tennis elbow will gain further traction in 2016 and beyond.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-eu-1599

PRP revenues in the UK—the largest market in Europe—will grow by 7.3% in 2016, an increase of 0.20% from the 7.1% growth in 2015. High prevalence of sports-related incidents in the U.K., combined with high awareness about the benefits of PRP therapy among healthcare community and patients, will continue to fuel the growth of the market in the country.

France will maintain its position as the second largest market for PRP in Europe, growing by 6.5% in terms of revenues in 2016. France is home to subsidiaries and distributors of several PRP players, such as Biomet, Inc., DePuy Synthes, Inc., and Stryker Corporation and a range of highly innovative products are available in the market.

Johnson & Johnson Inc. and Stryker Corporation are the established players in the Europe PRP market. Johnson & Johnson’s PEAK™ Platelet Rich Plasma System and Stryker Corporation’s RegenKit THT Autologous Platelet-rich Plasma (A-PRP) will continue to witness sizeable sales in 2016. Arthrex - Arthrex Angel System™ from Arthrex Inc. and GPS® III Platelet Separation System by Zimmer Biomet Holdings Inc. will also account for substantial revenue share of the Europe PRP market.

Ask The Analyst@ http://www.futuremarketinsights.com/askus/rep-eu-1599

Long-term Outlook: The PRP market in Europe is expected to increase at a CAGR of 6.6% during the forecast period 2016-2024. The UK will continue to be at the forefront of overall demand, with France and Germany accounting for sizeable market share. While FMI maintains a positive outlook on the Europe PRP market, challenges, including lack of standardisation in preparation and dosage of autologous blood concentrate, and uncertainty about therapy efficacy can impede growth during the forecast period.

ABOUT US:
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

CONTACT:
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Press@futuremarketinsights.com
Website: www.futuremarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Platelet Rich Plasma (PRP) Market to expand at a CAGR of 6.6% through 2016 to 2024 here

News-ID: 371304 • Views:

More Releases from Future Market Insights

Maca Magic Unleashed: Black Maca Extract Market Set to Hit USD 119.1 million by 2035 as Innovation Powers Wellness Boom
Maca Magic Unleashed: Black Maca Extract Market Set to Hit USD 119.1 million by …
The Quiet Revolution of Natural Wellness: Market Trajectory The global market for Black Maca Extract is experiencing a powerful, yet consistent, surge driven by the modern consumer's pivot toward natural and proactive health management. Far from a passing fad, this market is demonstrating robust and stable growth, with projections showing its value will nearly double over the next decade. Based on recent analysis, the market is set to expand from an
Fluoroquinolones ELISA Kit Market to Reach USD 144.7 Million by 2035 with 8.5% CAGR Growth
Fluoroquinolones ELISA Kit Market to Reach USD 144.7 Million by 2035 with 8.5% C …
The global fluoroquinolones ELISA kit market is set to undergo a decade of steady and transformative growth, rising from an estimated USD 64 million in 2025 to a projected USD 144.7 million by 2035. This expansion, at a compound annual growth rate (CAGR) of 8.5%, reflects the increasing need for accurate, reliable, and efficient diagnostic tools across industries such as food safety, pharmaceuticals, veterinary care, and environmental monitoring. From 2021 to
Medical Implants Precision Machining Service Market Poised for 6.4% CAGR Growth to 2035
Medical Implants Precision Machining Service Market Poised for 6.4% CAGR Growth …
Global Market Outlook: A Decade of Expanding Precision The medical implants precision machining service market is entering a decisive decade, with a strong growth trajectory driven by demand for advanced surgical solutions and innovations in multi-axis machining technologies. According to new projections, the market will expand from USD 1,056.4 million in 2025 to USD 1,964.5 million by 2035, marking a compound annual growth rate (CAGR) of 6.4%. Between 2021 and 2025, the
NGS Solution for Early Cancer Screening Market to Reach USD 2,393.5 million by 2035 Amid Precision Medicine Growth
NGS Solution for Early Cancer Screening Market to Reach USD 2,393.5 million by 2 …
Early Cancer Detection Enters a Transformative Era The fight against cancer is undergoing a profound transformation as the global healthcare sector accelerates the adoption of next-generation sequencing (NGS) technologies for early cancer detection. According to market forecasts, the NGS solution for early cancer screening market will grow from USD 591.6 million in 2025 to nearly USD 2,393.5 million by 2035, representing a 305% total growth and a 15% compound annual growth

All 5 Releases


More Releases for PRP

Therapeutic PRP Tubes Market to Witness Growth at a 6.6% CAGR by 2031 | Regen La …
QYResearch A newly published report titled "Global Therapeutic PRP Tubes Market 2025 is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Therapeutic PRP Tubes market. For instance, the market dynamics section digs deep into the
Global PRP Centrifuges Market Research Report 2023-2029
Global Leading Market Research Publisher QYResearch announces the release of its lastest report "Global PRP Centrifuges Market Report, History and Forecast 2018-2029, Breakdown Data by Manufacturers, Key Regions, Types and Application". Based on historical analysis (2018-2022) and forecast calculations (2023-2029), this report provides a comprehensive analysis of the global PRP Centrifuges market, including market size, share, demand, industry development status, and forecasts for the next few years. Provides advanced statistics
Latest Study on Platelet Rich Plasma (PRP) Market Future Growth Predictions and …
The Global Platelet Rich Plasma (PRP) Market 2019-2026 increase in the number of orthopedic surgeries and sports injuries and rise in the number of cosmetic surgeries are driving the growth of the market. However, high cost of devices & therapy will limit the market growth. The Global Platelet Rich Plasma (PRP) Market 2019 report includes Platelet Rich Plasma (PRP) Market Revenue, market Share, industry volume, and Trends, Growth aspects. Growing prevalence
Platelet Rich Plasma (PRP) Market is expected to grow at a CAGR of roughly 13.3% …
New Study Report On "Platelet Rich Plasma (PRP) Market is expected to grow at a CAGR of roughly 13.3% | Analysis By PRP Type (P-PRP, L-PRP, L-PRF), By Players (DePuy Synthes, Stryker...), By Surgery (Orthopedic, Cosmetic, General...) & Region, Size & Forecast To 2023" The worldwide market for Platelet Rich Plasma (PRP) is expected to grow at a CAGR of roughly 13.3% over the next five years, will reach 400 million
Platelet Rich Plasma Market By PRP Type (Pure-PRP, Leucocyte Rich PRP, Pure Plat …
Platelet rich plasma (PRP) is a portion of the plasma fraction of analogous blood, which contains platelet concentration more than standard concentration. Platelets contains bio proteins that helps in healing, tissue regeneration, and blood loss. Platelet rich plasma protein consists of three proteins, which acts as cell adhesive molecules that are fibrin, fibronectin, and vitronectin. The use of platelet rich plasma therapy is tremendously increased after 2009 due to its
Platelet Rich Plasma (PRP) Market Forecast 2017-2021
Platelet rich plasma (PRP) market has witnessed appreciable growth due to a growing number of devices being FDA approved in recent years; however the therapeutics market is anticipated to have an uncertain future, even as non-approved therapeutic applications flourish. Although various platelet rich plasma isolation devices have received 510(k) clearance, platelet rich plasma has not been approved for direct injection or implant without prior mixing with the bone graft materials.